BiotechTube
Cadence Neuroscience

Cadence Neuroscience

Seattle, United States· Est.
cadenceneuro.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $24M

Overview

Cadence Neuroscience is a private, clinical-stage medical device company pioneering a next-generation neuromodulation system for drug-resistant epilepsy. Incubated at Mayo Clinic and backed by venture capital, the company is developing a personalized therapy that aims to significantly increase the rate of seizure freedom compared to existing neurostimulation devices like VNS, RNS, and DBS. With a team of over 30 and strong clinical partnerships, Cadence is preparing for pivotal clinical studies to advance its lead program toward commercialization.

EpilepsyParkinson's disease

Technology Platform

Personalized, implantable closed-loop neuromodulation system combining proven hardware with novel, adaptive software for responsive brain stimulation.

Funding History

2
Total raised:$24M
Series A$20M
Seed$4M

Opportunities

The significant unmet need in drug-resistant epilepsy, where one-third of patients do not respond to medication, presents a large addressable market.
Cadence's personalized software approach could offer superior efficacy (seizure freedom) compared to existing neurostimulation devices, enabling market disruption and potential expansion into other neurological disorders.

Risk Factors

The company faces high clinical and regulatory risk, as its value proposition depends on unproven pivotal trial results.
It also competes against large, entrenched medical device companies with established products and sales channels, and must successfully execute the complex development and manufacturing of a software-driven implantable device.

Competitive Landscape

Cadence competes in the neuromodulation for epilepsy market against established devices: Vagus Nerve Stimulation (VNS, e.g., LivaNova), Responsive Neurostimulation (RNS, NeuroPace), and Deep Brain Stimulation (DBS, e.g., Medtronic). Its strategy is to differentiate through personalized, software-driven therapy aiming for a higher rate of seizure freedom, rather than just seizure reduction.

More companies in Neuroscience & CNS →More companies in United States →